Compare Freeport-McMoRan Inc (FCX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

FCX trades at $58.30, down 5.92% over 24 hours, with a neutral technical signal and bearish moving averages. The stock has consistently beaten earnings estimates, with Q2 2026 expected EPS of $0.60. Revenue grew to $25.92B in 2025, with net income of $2.20B and a net margin of 10.34%. The company maintains strong cash flow from operations of $5.61B and a dividend of $0.15 per share payable in August 2026.

FCX presents a favorable outlook with robust earnings performance and analyst consensus pointing to a $72.94 price target, implying significant upside. However, risks include commodity price volatility, high capital expenditures, and debt levels. The stock's current valuation at a P/E of 32.26 may limit near-term gains if growth moderates.

Zimmer Biomet (ZBH) trades at $92.94, up 2.1% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 70% gross margin and positive cash flow trends, though net income margin has declined from 13.8% in 2023 to 8.6% in 2025. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase, indicating management confidence.

ZBH presents a moderate growth opportunity with a consensus price target of $97.67, offering ~5% upside. Risks include rising debt levels and competitive pressures in medical devices. Analyst sentiment is mixed with 40% buy ratings, but institutional activity and strategic acquisitions support a stable outlook for long-term investors.